These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 13908035)

  • 21. [Action of triton on the system of the "clearing factor"].
    BIANCHINI P
    Boll Soc Ital Biol Sper; 1960 Mar; 36():273-7. PubMed ID: 13800420
    [No Abstract]   [Full Text] [Related]  

  • 22. [The clearing power of the plasma. New physiological data].
    LEMARCHANDS H; PARAMELLE B; SAVIER A
    Pathol Biol; 1961; 9():1491-5. PubMed ID: 24545813
    [No Abstract]   [Full Text] [Related]  

  • 23. [On the behavior of the plasma "clearing factor" after the administration of a synthetic heparinoid].
    CAMERADA P; CONGIU M; LEO P
    Boll Soc Ital Biol Sper; 1959 Nov; 35():1498-9. PubMed ID: 13807122
    [No Abstract]   [Full Text] [Related]  

  • 24. Studies of fat lipolysis by post-heparin human plasma lipoprotein lipase and by human pancreatic lipase.
    ENGELBERG H
    Circulation; 1959 Jun; 19(6):884-90. PubMed ID: 13663179
    [No Abstract]   [Full Text] [Related]  

  • 25. Lipoprotein substrates of lipoprotein lipase and hepatic triacylglycerol lipase from human post-heparin plasma.
    Musliner TA; Herbert PN; Kingston MJ
    Biochim Biophys Acta; 1979 Nov; 575(2):277-88. PubMed ID: 228741
    [No Abstract]   [Full Text] [Related]  

  • 26. [Activity of the clearing factor (lipoproteinase) in the blood plasma of children with rheumatism].
    SHARABARIN NI
    Vopr Okhr Materin Det; 1962 May; 7():30-3. PubMed ID: 13911342
    [No Abstract]   [Full Text] [Related]  

  • 27. [The clearing factor in normal subjects, in arteriosclerotic patients, in the aged and in diabetics].
    MOSSO HE; KATZ S; PERGOLA F
    Prensa Med Argent; 1961 Jul; 48():2035-40. PubMed ID: 14476560
    [No Abstract]   [Full Text] [Related]  

  • 28. [The influence of cutaneously applied hyaluronidase on thrombin inhibitor and the clearing factor of human plasma].
    STUETTGEN G; BRUESTER H
    Arch Klin Exp Dermatol; 1960; 210():27-33. PubMed ID: 13835418
    [No Abstract]   [Full Text] [Related]  

  • 29. [Protein and lipoprotein electrophoretic patterns and plasma clearing activity during treatment with 6 alpha-methyl-17 alpha-acetoxyprogesterone].
    TRONCONI G; FERRERO A
    Ann Ostet Ginecol; 1960 Jun; 82():735-41. PubMed ID: 13839463
    [No Abstract]   [Full Text] [Related]  

  • 30. Lipoproteins and lipolytic plasma enzymes in a case of tangier disease.
    Greten H; Hannemann T; Gusek W; Vivell O
    N Engl J Med; 1974 Sep; 291(11):548-52. PubMed ID: 4368872
    [No Abstract]   [Full Text] [Related]  

  • 31. [The role of various vascular regions in the liberation of the clearing factor after injection of heparin].
    LEMARCHAND H; PARAMELLE B
    J Physiol (Paris); 1961; 53():408-9. PubMed ID: 13760715
    [No Abstract]   [Full Text] [Related]  

  • 32. [Comparative study of various drugs and their action on lipids and the clearing factor].
    MOSSO HE; PERGOLA F; KATZ S
    Dia Med; 1962 Mar; 34():330-4. PubMed ID: 14476562
    [No Abstract]   [Full Text] [Related]  

  • 33. [On the estimation of the clearing power of the plasma].
    PARAMELLE B; LEMARCHANDS H
    C R Hebd Seances Acad Sci; 1960 Feb; 250():952-4. PubMed ID: 14430352
    [No Abstract]   [Full Text] [Related]  

  • 34. Role of lipoprotein lipases in postprandial lipid metabolism.
    Jansen H; Breedveld B; Schoonderwoerd K
    Atherosclerosis; 1998 Dec; 141 Suppl 1():S31-4. PubMed ID: 9888639
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Action of protamine on production and activity of heparin-induced clearing factor.
    MONKHOUSE FC; MCCLAIN F; BAKER DG
    Proc Soc Exp Biol Med; 1959 Oct; 102():50-3. PubMed ID: 14423573
    [No Abstract]   [Full Text] [Related]  

  • 36. Relationship between postheparin plasma lipases and high-density lipoprotein cholesterol in different types of diabetes.
    Laakso M; Sarlund H; Ehnholm C; Voutilainen E; Aro A; Pyörälä K
    Diabetologia; 1987 Sep; 30(9):703-6. PubMed ID: 3428502
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Postheparin plasma lipoprotein lipase and hepatic lipase in normal human subjects: relationship to age, sex and triglyceride metabolism.
    Huttunen JK; Ehnholm C; Kekki M; Nikkilä EA
    Adv Exp Med Biol; 1977; 82():146-8. PubMed ID: 920349
    [No Abstract]   [Full Text] [Related]  

  • 38. Clearing factor lipase (lipoprotein lipase) activator. A method for the measurement of the net activating ability of human sera.
    Rogers MP; Barnett D; Robinson DS
    Atherosclerosis; 1976 Sep; 24(3):551-64. PubMed ID: 184802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Deficiencies in the lipoprotein lipase system in atherosclerosis.
    PILGERAM LO
    J Gerontol; 1958 Jan; 13(1):32-42. PubMed ID: 13514035
    [No Abstract]   [Full Text] [Related]  

  • 40. The effects of post-heparin plasma lipases on anti-Xa clotting activity.
    Williams SP; Barrowcliffe TW
    Thromb Res; 1985 Feb; 37(3):371-7. PubMed ID: 3992526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.